A phase I study of paclitaxel in combination with SU011248 [sunitinib ] for patients with breast cancer as first-line treatment in the advanced disease setting
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Paclitaxel (Primary) ; Sunitinib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 05 Oct 2008 Planned end date (Aug 2007) added as reported by CT.gov
- 05 Oct 2008 Status changed from active, no longer recruiting to completed as reported by CT.gov
- 05 Oct 2008 Actual number of patients (22) added as reported by CY.gov